Armune BioScience, a developer of a blood test that assesses the risk of prostate cancer, has secured $5 million in Series A funding. The investors included Grand Angels.
Source: Press Release
Armune BioScience, a developer of a blood test that assesses the risk of prostate cancer, has secured $5 million in Series A funding. The investors included Grand Angels.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: